XOMA Corporation (XOMA) Proxy filing summary

Executive summary

• Stockholders are asked to approve a merger in which their shares will be converted into $39.00 per share in cash plus one contingent value right (CVR) per share, tied to the outcome of pending litigation against Janssen Biotech, Inc.

• The merger is structured to include a holding company reorganization, after which the company will become a wholly owned subsidiary of the acquirer, Ligand Pharmaceuticals.

• All preferred stock will be redeemed prior to the merger, with accrued dividends paid, and equity awards and warrants will be treated as specified in the merger agreement.

• The board recommends voting in favor of all proposals, citing a thorough market check, premium to recent share prices, and the opportunity for additional upside via the CVR.

Voting matters and shareholder proposals

• Four proposals are up for vote: approval of the merger agreement, approval of the holding company reorganization, a non-binding advisory vote on executive compensation, and the ability to adjourn the meeting if necessary.

• Approval of the merger and reorganization proposals requires a majority of outstanding voting power; compensation and adjournment proposals require a majority of votes cast.

• Certain major shareholders, including directors and BVF Partners (holding over 44% of shares), have entered into support agreements to vote in favor.

• Stockholders have dissenter's rights under Nevada law if they do not vote in favor and follow statutory procedures.

Board of directors and corporate governance

• The board conducted a comprehensive review of strategic alternatives, engaged financial advisors, and negotiated with multiple parties before recommending the merger.

• The holding company reorganization will result in the same directors and bylaws for the new parent entity as existed prior to the transaction.